T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Tanta University
Icahn School of Medicine at Mount Sinai
Peking University Cancer Hospital & Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
Hebei Medical University Fourth Hospital
Providence Health & Services
Stanford University
Washington University School of Medicine
University of Wisconsin, Madison
UNC Lineberger Comprehensive Cancer Center
Xijing Hospital
UNC Lineberger Comprehensive Cancer Center
Odense University Hospital
Abramson Cancer Center at Penn Medicine
University of California, San Diego
Sun Yat-sen University
Hoosier Cancer Research Network
Fudan University
Damanhour University
Alliance for Clinical Trials in Oncology
MedSIR
Rutgers, The State University of New Jersey
The Methodist Hospital Research Institute
Dana-Farber Cancer Institute
Spanish Breast Cancer Research Group
Hebei Medical University Fourth Hospital
Sun Yat-sen University
H. Lee Moffitt Cancer Center and Research Institute
D'Or Institute for Research and Education
Chinese University of Hong Kong
Institut Cancerologie de l'Ouest
Washington University School of Medicine
Mayo Clinic
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
University of Texas Southwestern Medical Center
Institute of Cancer Research, United Kingdom
University of Colorado, Denver
Centre Oscar Lambret
SOLTI Breast Cancer Research Group
Shanghai Jiao Tong University School of Medicine
Wake Forest University Health Sciences